65746 Federal Register / Vol. 66, No. 245 / Thursday, December 20, 2001 / Notices

Drug Schedule

Alfentanil (9737) .......................................................................................................................................................................................... II

Sufentanil (9740) ......................................................................................................................................................................................... II

Fentanyl (9801) ........................................................................................................................................................................................... II

The firm plans to manufacture small

quantities of the listed controlled

substances to make deuterated and nondeuterated drug reference standards

which will be distributed to analytical

and forensic laboratories for drug testing

programs.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substance

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistance Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, DC 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than February

19, 2002.

Dated: November 16, 2001.

Laura M. Nagel,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 01–31280 Filed 12–19–01; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Registration

By Notice dated March 29, 2001, and

published in the Federal Register on

April 6, 2001, (66 FR 18310), Isotec Inc.,

3858 Benner Road, Miamisburg, Ohio

45342, made application by renewal to

the Drug Enforcement Administration

(DEA) to be registered as a bulk

manufacturer of the basic classes of

controlled substances listed below:

Drug Schedule

Cathinone (1235) ......................................................................................................................................................................................... I

Methcathinone (1237) .................................................................................................................................................................................. I

N-Ethylamphetamine (1475) ........................................................................................................................................................................ I

N,N-Dimethylamphetamine (1480) .............................................................................................................................................................. I

Aminorex (1585) .......................................................................................................................................................................................... I

Methaqualone (2565) .................................................................................................................................................................................. I

Lysergic acid diethylamide (7315) ............................................................................................................................................................... I

Tetrahydrocannabinols (7370) ..................................................................................................................................................................... I

Mescaline (7381) ......................................................................................................................................................................................... I

2,5-Dimethoxyamphetamine (7396) ............................................................................................................................................................ I

3,4-Methylenedioxyamphetamine (7400) .................................................................................................................................................... I

3,4-Methylenedioxy-N-ethylamphetamine (7404) ........................................................................................................................................ I

3,4-Methylenedioxymethamphetamine (7405) ............................................................................................................................................ I

4-Methoxyamphetamine (7411) ................................................................................................................................................................... I

Psilocybin (7437) ......................................................................................................................................................................................... I

Psilocyn (7438) ............................................................................................................................................................................................ I

N-Ethyl-1-phenylcyclohexylamine (7455) .................................................................................................................................................... I

Dihydromorphine (9145) .............................................................................................................................................................................. I

Normorphine (9313) .................................................................................................................................................................................... I

Acetylmethadol (9601) ................................................................................................................................................................................. I

Alphacetylmethadol Except Levo-Alphacetylmethadol (9603) .................................................................................................................... I

Normethadone (9635) ................................................................................................................................................................................. I

3-Methylfentanyl (9813) ............................................................................................................................................................................... I

Amphetamine (1100) ................................................................................................................................................................................... II

Methamphetamine (1105) ........................................................................................................................................................................... II

Methylphenidate (1724) ............................................................................................................................................................................... II

Amobarbital (2125) ...................................................................................................................................................................................... II

Pentobarbital (2270) .................................................................................................................................................................................... II

Secobarbital (2315) ..................................................................................................................................................................................... II

1-Phenylcyclohexylamine (7460) ................................................................................................................................................................. II

Phencyclidine (7471) ................................................................................................................................................................................... II

Phenylacetone (8501) ................................................................................................................................................................................. II

1-Piperidinocyclohexanecarbonitrile (8603) ................................................................................................................................................ II

Codeine (9050) ............................................................................................................................................................................................ II

Dihydrocodeine (9120) ................................................................................................................................................................................ II

Oxycodone (9143) ....................................................................................................................................................................................... II

Hydromorphone (9150) ............................................................................................................................................................................... II

Benzoylecgonine (9180) .............................................................................................................................................................................. II

Ethylmorphine (9190) .................................................................................................................................................................................. II

Hydrocodone (9193) .................................................................................................................................................................................... II

Isomethadone (9226) .................................................................................................................................................................................. II

Meperidine (9230) ....................................................................................................................................................................................... II

Methadone (9250) ....................................................................................................................................................................................... II

Methadone intermediate (9254) .................................................................................................................................................................. II

Dextropropoxyphene, bulk (non-dosage forms) (9273) .............................................................................................................................. II

Morphine (9300) .......................................................................................................................................................................................... II

Thebaine (9333) .......................................................................................................................................................................................... II

Levo-Alphacetylmethadol (9648) ................................................................................................................................................................. II

Federal Register / Vol. 66, No. 245 / Thursday, December 20, 2001 / Notices 65747

Drug Schedule

Oxymorphone (9652) ................................................................................................................................................................................... II

Fentanyl (9801) ........................................................................................................................................................................................... II

The firm plans to manufacture small

quantities of the listed controlled

substances to produce standards for

analytical laboratories.

No comments or objections have been

received. DEA has considered the

factors in Title 21, United States Code,

section 823(a) and determined that the

registration of Isotec, Inc. to

manufacture the listed controlled

substances is consistent with the public

interest at this time. DEA has

investigated the company on a regular

basis to ensure that its continued

registration is consistent with the public

interest. These investigations have

included inspection and testing of the

company’s physical security systems,

audits of the company’s records,

verification of the company’s

compliance with state and local laws,

and a review of the company’s

background and history. Therefore,

pursuant to 21 U.S.C. 823 and 28 CFR

0.100 and 0.104, the Deputy Assistant

Administrator, Office of Diversion

Control, hereby orders that the

application submitted by the above firm

for registration as a bulk manufacturer

of the basic classes of controlled

substances listed above is granted.

Dated: November 15, 2001.

Laura M. Nagel,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 01–31281 Filed 12–19–01; 8:45 am]

BILLING CODE 4410–09–M

NATIONAL ARCHIVES AND RECORDS

ADMINISTRATION

Report on Current Recordkeeping

Practices in the Federal Government;

Request for Comment

AGENCY: National Archives and Records

Administration (NARA).

ACTION: Notice of availability of report;

request for comment.

SUMMARY: NARA is seeking public

comment on the Report on Current

Recordkeeping Practices within the

Federal Government. The report is an

analysis of two significant data

collections that were conducted by

NARA and SRA International, Inc.

(SRA) to assess the state of

recordkeeping and records use in the

Federal Government. This is an

important step in NARA’s efforts to

review and, if necessary, revise records

management policies and guidance to fit

the changing office environment.

The report is available electronically

at http://www.nara.gov/records/

rmi.html. For a paper copy of the report,

contact the person listed in FOR FURTHER

INFORMATION CONTACT.

DATES: Comments must be received by

January 31, 2002.

ADDRESSES: Please send comments to

comments@nara.gov, or fax them to

301–713–7270, or mail them to NARA

(NPOL), 8601 Adelphi Rd. Rm. 4100,

College Park, MD 20740–6001

FOR FURTHER INFORMATION CONTACT:

Susan Cummings at 301–713–7360

x238.

SUPPLEMENTARY INFORMATION: NARA has

undertaken three initiatives to

document the current recordkeeping

and records use environment in Federal

agencies, to use that information to

analyze NARA’s records management

policies, and to redesign, if necessary,

the scheduling and appraisal process.

This report is the result of the first

initiative.

SRA used individual interviews,

focus groups, and an Internet survey to

find out how agency officials and staff

viewed records management and what

they perceived its role to be in today’s

modern office. More than 40 Federal

agencies participated in the interviews

and focus groups, and more than 475

individuals replied to the Internet

survey. Additionally, using a process

called Records Systems Analyses, or

RSAs, NARA teams examined selected

business processes in Federal agencies

to determine how records are actually

being created and managed. The report

identifies patterns in records

management, suggests situational

models to explain those patterns, and

identifies points where NARA could

effectively intervene to improve records

management.

Dated: December 14, 2001.

Nancy Allard,

Federal Register Liaison.

[FR Doc. 01–31341 Filed 12–19–01; 8:45 am]

BILLING CODE 7515–01–P

NATIONAL CREDIT UNION

ADMINISTRATION

Community Development Revolving

Loan Program for Credit Unions

AGENCY: National Credit Union

Administration.

ACTION: Notice of application period.

SUMMARY: The National Credit Union

Administration (NCUA) will accept

applications for participation in the

Community Development Revolving

Loan Fund’s Loan Program throughout

calendar year 2002, subject to

availability of funds. Application

procedures for qualified low-income

credit unions are in NCUA Rules and

Regulations.

ADDRESSES: Applications for

participation may be obtained from and

should be submitted to: NCUA, Office of

Credit Union Development, 1775 Duke

Street, Alexandria, VA 22314–3428.

DATES: Applications may be submitted

throughout calendar year 2002.

FOR FURTHER INFORMATION CONTACT: The

Office of Credit Union Development at

the above address or telephone (703)

518–6610.

SUPPLEMENTARY INFORMATION: Part 705 of

the NCUA rules and regulations

implements the Community

Development Revolving Loan Program

for Credit Unions. The purpose of the

Program is to assist officially designated

‘‘low-income’’ credit unions in

providing basic financial services to

residents in their communities that

result in increased income, ownership

and employment. The Program makes

available low interest loans in amounts

up to $300,000 in the aggregate to

qualified participating ‘‘low-income’’

credit unions. Program participation is

limited to existing credit unions with an

official ‘‘low-income’’ designation.

Student credit unions are not eligible to

participate in this program.

This notice is published pursuant to

section 705.9 of the NCUA rules and

regulations that states NCUA will

provide notice in the Federal Register

when funds in the program are

available.

By the National Credit Union

Administration Board on December 13, 2001.

Becky Baker,

Secretary of the Board.

[FR Doc. 01–31289 Filed 12–19–01; 8:45 am]

BILLING CODE 7535–01–P